Allouche Cyril
Principal Accounting Officer at Revance Therapeutics, Inc.
- Sold, on record
- $99k
- Dollars the filings state
- Form 4 sales
- 6
- Latest Mar 18, 2019
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- Revance Therapeutics, Inc.Principal Accounting Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale Revance Therapeutics, Inc.Plan not statedJul 6 2018
Sold 393 shares at $28.35 ($11k)
Allouche Cyril, Principal Financial Officer
Sold 7.6% of holdings ($146k position)4,750 shares leftFirst sale on recordFiling
- 2 Form 4 sale Revance Therapeutics, Inc.UnusualNov 9 +126 days
Sold 2,188 shares at $23.72 ($52k)
Allouche Cyril, Principal Accounting Officer
Sold 31.5% of holdings ($165k position)4,750 shares leftFiling
- 3 Form 4 sale Revance Therapeutics, Inc.Plan not statedNov 20 +11 days
Sold 491 shares at $20.66 ($10k)
Allouche Cyril, Principal Accounting Officer
Sold 10.9% of holdings ($93k position)4,000 shares leftFiling
- 4 Form 4 sale Revance Therapeutics, Inc.Plan not statedJan 3 +44 days
Sold 375 shares at $19.48 ($7k)
Allouche Cyril, Principal Accounting Officer
Sold 8.6% of holdings ($85k position)4,000 shares left0.8x usual sizeFiling
- 5 Form 4 sale Revance Therapeutics, Inc.Plan not statedJan 22 +19 days
Sold 625 shares at $17.77 ($11k)
Allouche Cyril, Principal Accounting Officer
Sold 13.5% of holdings ($82k position)4,000 shares left1.4x usual sizeFiling
- 6 Form 4 sale Revance Therapeutics, Inc.Plan not statedMar 18 +55 days
Sold 498 shares at $15.48 ($8k)
Allouche Cyril, Principal Accounting Officer
Sold 7.2% of holdings ($107k position)6,400 shares left1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (6)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Mar 18, 2019 | Revance Therapeutics, Inc. | Principal Accounting Officer | Form 4 sale | 498 | $8k | 7.2% | Plan not stated | SEC |
| Jan 22, 2019 | Revance Therapeutics, Inc. | Principal Accounting Officer | Form 4 sale | 625 | $11k | 13.5% | Plan not stated | SEC |
| Jan 3, 2019 | Revance Therapeutics, Inc. | Principal Accounting Officer | Form 4 sale | 375 | $7k | 8.6% | Plan not stated | SEC |
| Nov 20, 2018 | Revance Therapeutics, Inc. | Principal Accounting Officer | Form 4 sale | 491 | $10k | 10.9% | Plan not stated | SEC |
| Nov 9, 2018 | Revance Therapeutics, Inc. | Principal Accounting Officer | Form 4 sale | 2,188 | $52k | 31.5% | Unusual | SEC |
| Jul 6, 2018 | Revance Therapeutics, Inc. | Principal Financial Officer | Form 4 sale | 393 | $11k | 7.6% | Plan not stated | SEC |